Hospital Centralized Monitoring of Post-market Clinical Safety of Naoxintong Capsules in 7 345 Patients
10.13422/j.cnki.syfjx.20240293
- VernacularTitle:7 345例脑心通胶囊上市后临床安全性的医院集中监测
- Author:
Chunxiao LI
1
;
Xiao LING
1
;
Xuelin LI
1
;
Jinfa TANG
1
;
Yuhuan CHEN
1
;
Hui ZHANG
1
;
Tao XU
1
;
Yantao JIN
1
;
Bo ZHANG
1
Author Information
1. The First Affiliated Hospital of Henan University of Chinese Medicine， Zhengzhou 450000， China
- Publication Type:Journal Article
- Keywords:
Naoxintong capsules;
safety;
adverse reactions;
hospital centralized monitoring
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2023;29(17):157-165
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo evaluate the clinical safety of Naoxintong （NXT） capsules after marketing， find out the potential risk factors of the drug as soon as possible， and reveal the incidence， nature， and clinical manifestations of the adverse events （ADE） and adverse reactions （ADR） of NXT capsules， so as to provide a basis for safe use of the drug in clinical practice. MethodA prospective， large-sample， multi-center observational cohort study was conducted to monitor all the 7 345 inpatients and outpatients orally taking NXT in 14 hospitals in China from January to December in 2018， with at least one follow-up. The demographic characteristics， disease type， NXT medication， ADR occurrence， characteristics， and prognosis of the patients were collected. SPSS 23.0 was used for single-factor and multivariate logistic regression to predict the influencing factors of ADR. ResultThe male and female patients accounted for similar proportions. There were 5 081 patients （79.40%） aged ≥60 years and 3 153 patients （49.27%） with body mass index （BMI） exceeding the normal standard. There were 344 （5.38%） patients with a history of allergy to medicines and food， 9 （0.14%） patients with a family history of allergy， and 52 （0.81%） patients with a history of allergic diseases. The ADRs associated with NXT occurred in 22 patients， with the incidence of 0.34%. The clinical manifestations of ADR appeared in 31 cases， involving 10 organs/systems， of which gastrointestinal system damage was the most common （17， 54.84%）. All ADRs were mild or moderate. Most ADRs （19， 86.36%） occurred within 4 weeks after administration. The patients with alleviated NXT-associated ADRs accounted for 81.82%. No indicators related to significant increases in ADR risks were found. ConclusionNXT is well tolerated in the general population. The hospital centralized monitoring for the clinical safety of oral Chinese patent drugs based on HIS data and Web tracking and follow-up system is an essential means for the post-market research on the safety of drugs.
